Sarah B. Noonberg is on the board of Protagonist Therapeutics, Inc. and Neoleukin Therapeutics, Inc. In the past she was Chief Medical Officer for Prothena Corp. Plc, Chief Medical Officer at Nohla Therapeutics, Inc., Chief Medical Officer at Maze Therapeutics, Inc., Group VP & Head-Global Clinical Development at BioMarin Pharmaceutical, Inc., Director-Clinical Development at Chiron Corp. and SVP-Early Development & VP-Clinical Development at Medivation LLC (California).

She received a doctorate from The University of California, San Francisco, a doctorate from the University of California, Berkeley and an undergraduate degree from Dartmouth College.